World-class
Scientific Advisory

Work with Richmond Pharmacology and trust your experience will be personal and truly strategic.

What makes us special?

Work with Richmond Pharmacology and trust your experience will be personal and truly strategic.

What makes us special?

Richmond Pharmacology delivers clinical excellence from design to delivery. Our long-term working relationships with our international client-base has led to the completion of over 500 Early Phase Studies.

We provide a personal service. Our founders are influential clinical research experts and lead each clinical trial. Our team of senior drug development experts are also on hand to ensure the quality, integrity, and accuracy of your study. We are reputed for our customer-centric project management, our flexible approach, and the superior quality of the studies. As a sponsor, you will have high-level engagement and meaningful peer to peer conversations.

Accredited by the MHRA, we guarantee that our trials adhere to the highest clinical, ethical and safety standards and our processes are auditable.

Our efficient and adaptive approach leads to faster development times, accelerating the time to market from first in human trials to proof of concept in under nine months. Adding value by integrating ethnic comparison elements and intensive cardiac assessments.


The clinical unit is in the heart of London with easy access to mainline train stations and airports, making it the ideal location to attract research volunteers.

Richmond Pharmacology’s volunteer database exceeds 250,000 individuals from a broad demographic spectrum and a wide variety of patient panels across rare to more common diseases. The database grows by 1000 to 2000 volunteers each month with a typical 70/30 split between healthy volunteers and patients.

Latest news

Upcoming Event

ACCP 2020, Translating Clinical Pharmacology Research into Patient-centered Care

21 - 23 September 2020
Dr. Jorg Taubel will be presenting posters that explore the subjects of cardiac health and diabetes.
View event

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

October 20, 2020
Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
Read more

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more

Richmond Pharmacology helps UK patients gain early access to ultra-rare disease drug Lumasiran

August 17, 2020
Richmond Pharmacology early phase drug development update.
Read more